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Abstract
Staphylococcus aureus is a Gram-Positive bacteria that are responsible to cause 
skin infections and also shows toxic shock syndrome. Several antibiotics were given 
against the S. aureus infections but eventually, the prevalence of multidrug resis-
tance of Staphylococcus aureus started emerging. Since then Methicillin-resistant 
Staphylococcus aureus strains (MRSA)were very common which causes nosocomial 
infections. Microorganisms for the need of the survival undergoes mutational 
changes either in their chromosomal DNA/RNA which confers the resistance. 
One of the famous examples is the resistance against methicillin in Staphylococcus 
aureus. The evolution of S. aureus is successful in developing multiple resistant 
strains. Plasmids are capable of carrying the resistant genes and also several toxic 
genes. In a recent study, it has been observed that drug resistance genes are located 
in the R plasmids and they are also responsible in conferring multi drug resistance 
and induce less utilization of multiple antimicrobial therapy. MRSA was not only 
resistant to methicillin, studies proved MRSA strains were resistant to macrolides, 
tetracyclines, chloramphenicol. Resistance to vancomycin was very evidently 
observed, and its transfer among the population and rising of resistant strains was 
becoming a major threat globally. The resistance of all these antimicrobial agents 
against the pathogenic microorganisms are taking a rise in some patients due to 
prolong use of the antimicrobial agents by these patients. The multi drug resistance 
has enhanced the mortality and morbidity rate which referred to the infecting 
agents as the “Super Bugs”. Survival of the microorganisms has increased due to the 
gradual development of extensive resistance against varied antimicrobial drugs. 
Possible treatments with combinations are found to be the only hope for infections 
against S. aureus. Few drugs are in development such as Dalbavancin, Oritavancin, 
Tigecycline. These are the possible treatments upon which the work is going on 
to reduce the resistance against the invasive MRSA. This chapter highlights the 
profiles of Staphylococcus aureus and the resistance patterns along with transmission 
and the role of the plasmid in transmitting the resistance.
Keywords: multi-drug resistance, SaPIs, mec A gene, clinical MDR, daptomycin, 
dalbavancin
1. Introduction
Multi-Drug Resistance of S. aureus is a massive concern in the clinical world. 
Immunocompromised, diabetic, and weak immune systems are general medical 
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problems but patients already suffering from these are more susceptible to the 
Staphylococcal infections and mainly by S. aureus which causes skin infections and 
soft tissue infections. The severity of the infections caused by S. aureus increases 
when there is overgrowth of the S. aureus on the infected part of the body which 
results in the secretion of toxins and causes a fatal condition known as toxic shock 
syndrome. Penicillin was used predominantly against infections caused by S. aureus 
but the organism started having resistant strains developed for fighting against 
Penicillin. Methicillin was the next approach that came up for S. aureus but the 
major failure of methicillin by forming MRSA strains made vancomycin the last 
hope for S. aureus infections. Methicillin is the synthetic antibacterial drug given 
to S. aureus widely. S. aureus is resistant to almost all antibiotic drugs that are so 
far used and among them Methicillin and Vancomycin are the two drugs that have 
shown resistance in S. aureus. In this, we will emphasize the genetic aspects of the 
resistance that is observed in S. aureus. The antibiotic resistance genes are gener-
ally present on plasmids, and nonessential for the survival of the organism but it 
provides the bacterial population with a means to reduce the genetic and physio-
logical load on the majority of cells. Plasmid-borne genes can undergo more radical 
evolutionary changes without affecting the viability of the cell, as would changes to 
indispensable chromosomal genes, and established plasmid transfer mechanisms 
can provide recipient cells with new genetic material which has already been refined 
by selective pressures elsewhere. Besides plasmids, bacteriophages too have con-
tributed towards development of resistance by transduction. Thus the continuous 
evolution of S. aureus strains was successful to bring forth the vancomycin-resistant 
strains as well (VRSA). New drug development and treatments are applied to the S. 
aureus mediated infections which have proved to be the immediate possible treat-
ment for this. This chapter will help the readers to acquire a comprehensive knowl-
edge regarding the Multi-Drug Resistance of S. aureus along with the resistance 
mechanism and possible treatments of Staphylococcal infections.
2. Multi-drug resistance
2.1 Overview of multi-drug resistance
Multi-Drug Resistance (MDR) is a global concern that is having a very bad 
impact on health care. Microbes are getting resistant to antibiotic therapies due to 
the constant exposure of antimicrobial drugs. In the past decade, microbial infec-
tions have raised enormously and this has led to an increased amount of resistance 
[1]. Multi drug resistance is the phenomenon in which pathogenic organisms are 
resistant to multiple chemotherapeutic agents [2]. The emergence of MDR rises the 
mortality and morbidity rates for which they are known as ‘Superbugs’. It is said that 
MDR is a very natural process among microorganisms but the increasing amount of 
this process is due to several reasons like the use of undefined antimicrobial agents, 
unhygienic sanitary conditions, poor health care facilities. The omnipresent threat 
of antibiotic-resistant pathogens entails having very few antimicrobial agents for 
other infections [2, 3].
2.2 Classification of MDR
Many different definitions for multidrug-resistant (MDR), extensively drug-
resistant (XDR) and pandrug-resistant (PDR) bacteria are being used to character-
ize the different patterns of resistance. Was defined as acquired non-susceptibility 
to at least one agent in three or more antimicrobial categories, XDR was defined 
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as non-susceptibility to at least one agent in all but two or fewer antimicrobial 
categories (i.e. bacterial isolates remain susceptible to only one or two categories) 
and PDR was defined as non-susceptibility to all agents in all antimicrobial cat-
egories. MDR is a frequently encountered phenomenon in S. aureus which can be 
broadly classified as primary MDR, secondary MDR and clinical MDR (Figure 1) 
[1, 4–6]. Survival of the microorganisms has gradually developed extensive resis-
tance against varied antimicrobial drugs. Also, there is a failure of many clinical 
trials which are not always due to the occurrence of resistance but all due to poor 
bioavailability of drugs, very poor immune system, excessive-high metabolism 
of drugs.
2.3 Mechanism of multi-drug resistance (MDR)
Before studying the resistance of S. aureus, it is very important to take a look 
upon all the possible biochemical mechanisms of resistance that the microbes 
show. Microorganisms have the ability to employ several ways to develop multi 
drug resistance [2]. The resistance of all these antimicrobial agents against the 
pathogenic microorganisms are taking a rise in some patients due to prolong use of 
the antimicrobial agents by these patients. Below, is the schematic diagram of all 
methods of resistance mechanism (Figure 2). Microorganisms for the need of the 
survival undergoes mutational changes either in their chromosomal DNA/RNA 
which confers the resistance. One of the famous examples is the resistance against 
methicillin in Staphylococcus aureus. The cell wall of the microbes plays a vital role as 
a barrier and helps in their survival but due to alteration in the chromosomal DNA 
or genetic mutations the compositions of the cell wall or the plasma membrane 
changes and this in turn encourage the resistance phenomenon.
Drug Efflux Pumps are one of the major ways for the MDR mechanism. ABC 
transporters (ATP Binding Cassette) are membrane proteins which are com-
monly defined as drug efflux pumps that specifically helps in the transport of the 





the permeability and influences the ATP-dependent efflux of the drugs which is 
responsible for decreasing the intracellular concentrations [7–9].
3. Genetic aspect of resistance in S. aureus
The genetic determinants of resistance to many antimicrobial agents are 
believed to have evolved prior to the era of antibiotic chemotherapy. Processes 
such as phosphorylation, glycosylation, acetylation whose inactivation or chemical 
transformation is the major cause of the MDR. The schematic diagram shows the 
possible ways of causing antimicrobial resistance (Figure 3) [1, 4, 10–12].
Methicillin-Resistant Staphylococcus aureus (MRSA) came into the focus of atten-
tion when the Methicillin-Susceptible Staphylococcus aureus (MSSA) started adopt-
ing a specific gene (methicillin-resistant gene) named as mecA which is intervened 
by a genetic element called Staphylococcus cassette chromosome (SCC) and is 
transferred into the MSSA via either conjugation or transformation (Horizontal 
gene transfer). As SCC elements are carrying the gene mecA so, the complex is 
named SCCmec. The complex consists of the mecA and several other regulatory 
genes such as mecR1, mecI. (Figure 4), Demonstrate a schematic diagram of the 
SSCmec element. There is also the presence of a specific complex named Cassette 
Chromosome Recombinase (CCR) that helps in the integration and excision of 
the element from the chromosome of Staphylococcal species [13–16]. The region, 
origin of replication (oriC) in the S. aureus chromosomal element is accompanied 
by a special gene named as orfX towards the downstream of the oriC. The gene 
orfX is popular for encoding a specific enzyme called ribosomal RNA methyl-
transferase and this gene also has direct repeat sequences that help to protect the 
Staphylococcus cassette chromosome (SCC). In this way, multiple SCC elements are 
placed one after another in tandem which results in the formation of the cluster of 
foreign genes and forms a chromosomal region whose name is oriC environ  
[13, 17, 18]. Now, there are mainly two types of MRSA. One, the Community-
Associated MRSA (CA-MRSA), and the other one is Hospital-Acquired MRSA 
(HA-MRSA). CA-MRSA has been found to get transmitted among the population 
from crowded places and the CA-MRSA isolates are highly resistant against methi-
cillin and penicillin as well. Minor skin problems, redness, itchiness, and pain are 
the symptoms of the body affected by CA-MRSA. HA-MRSA is acquired from the 
hospital or any health care center. oriC environ has many transposons and insertion 
sequences (IS) which are capable to induce deletion, recombination, chromosomal 
Figure 2. 
Multi drug resistance mechanism.
5
Antimicrobial Resistance in Staphylococcus aureus
DOI: http://dx.doi.org/10.5772/intechopen.96888
inversion across oriC and this helps the S. aureus to maintain their survival strategy 
according to the environmental condition [18]. Horizontal gene transfer mediated 
by phage is one of the prime reason for the evolution of the S. aureus. It has been 
observed in the past studies that the Bacteriophages such as Staphylococcus Phage 
80α is a specific helper bacteriophage that is required for the mobilization of SaPIs. 
This helps to carry the Staphylococcus aureus pathogenicity islands (SaPIs). SaPIs are 
known as mobile genetic elements which are the common residents in the genome 
of S. aureus and are transferred to other cells. These SaPIs are responsible for carry-
ing several toxin genes and also superantigens [19, 20].
Plasmids are capable of carrying the resistant genes and also several toxic 
genes. In a recent study, it has been observed that when an S. aureus plasmid was 
sequenced which originated from a different bacterial environment, few trailblaz-
ing resistance genes named ampA and vgaC were discovered. The amp resistance 
gene is resistant to the antimicrobial drug named apramycin and the vgaC resis-
tance gene is resistant against Streptogramin A, respectively. Along with these, 
many toxin genes are being carried on S. aureus plasmids such as exotoxin B (ETB) 
and enterotoxins (entA, entP, entG, entJ). R plasmids play a major role in mediating 
resistance among bacteria. Drug resistance genes are located in the R plasmids and 
they are also responsible in conferring multi drug resistance and induce less utiliza-
tion of multiple antimicrobial therapy [21–23].
There is also support for the notion that some resistance determinants in 
staphylococci are derived from genes present in antibiotic-producing organisms. 
The S. aureus ermC methylase encoded on pE194 shares amino acid sequence 
Figure 4. 
A schematic diagram of SCCmec element. The SCCmec consists of two components mec. A gene complex and 
ccr gene complex. mec gene complex helps to encode the methicillin resistance gene(mec A) and other two 
regulatory genes (mecR1, mec1). ccr gene complex takes care of the movement of the whole SCC element.
Figure 3. 
Schematic diagram of antimicrobial resistance.
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homology with the analogous methylase encoded by erythromycin-producing 
organisms such as Streptomyces erythraeus (ermE) [24].
4. Resistance against antibiotics
Due to the high resistance against methicillin and after the failure of the drug, 
Vancomycin was playing a major role in treating most MRSA infections. Isolates of 
S. aureus were taken from a surgical wound of a Japanese baby and it was observed 
that the infection was not responding to the drug called Vancomycin. Vancomycin, is 
an antibiotic made up of glycopeptide and was initially used for the treatment of the 
MRSA strains as the efficacy of this drug was quite prominent but eventually because 
of prolong usage of the drug, it was resistant to MRSA infections. The resistance was 
not via the acquisition of vanA by MRSA infection-causing strain but this was because 
of unusual thickening of the cell wall which is rich in dipeptides and this results in the 
decreasing of the drug availability in the body. Despite the issues, in the year 2000, 
Vancomycin was considered to be one of the prominent drugs against the MRSA strains. 
The mechanism of the resistance is predicted to be a plasmid-mediated transfer among 
the species. The genes vraS, msrR, rpoB and graR were found to be mutated which 
was responsible for the resistance against the Vancomycin [13, 25–27]. Other than 
Methicillin and Vancomycin, Penicillin and Quinolones were also given to S. aureus.
In case of Penicillin, R plasmids encode the enzyme called as penicillinase, the 
plasmid gene that carries the enzyme is blaz, and the organisms that were resistant 
to penicillin were having this gene which inactivated the antibiotic by splitting the 
β-lactam ring. Slowly, this became a threat and major resistance towards penicillin 
antibiotic emerged world wide [28–30]. Use of Methicillin started when Penicillin 
failed to cure the Staphylococcal infections. After major failure of both these 
antibiotics, Quinolones were used. Quinolones destroy the bacteria by attacking and 
inhibiting their bacterial topoisomerases which generally ease the super coiling of 
DNA and also separates DNA strands. Moxifloxacin and Gemifloxacins are useful 
against the Gram-Positive bacteria but unfortunately S. aureus again developed 
resistance against quinolones [31, 32]. S. aureus developed resistance against fluoro-
quinolones by overexpression of the NorA efflux pumps. Similarly, point mutation 
is another way by which this organism becomes resistant to quinolones. Point muta-
tion in the subunits of topoisomerase takes place. Such as, point mutation at Gr1A 
in topoisomerase IV subunit and in GyrA, subunit of Gyrase [28].
4.1 Transmission pattern of resistance
Transmission of MRSA infections can take place from person to person who is 
contaminated with such infections. Proper hygienic condition is required to main-
tain infection from getting spread. Although the mode of transmission of infections 
mainly relies upon direct contact but contact with contaminated fomites can also 
transmit the infection. Several other factors of the host such as immunocompro-
mised patients, defects in neutrophils, or destruction of the skin barriers can also 
give rise to the infections. Staphylococcus aureus has shown evolutionary changes 
in it and this phenomenon completely relies on the plasmid gene transfer mecha-
nisms. The conventional mechanisms such as horizontal gene transfer popularly 
conjugation and transformation are followed by the strains to spread the resistance 
among the population or community but there is a very unique mechanism of 
Staphylococcus named SaPI-helper phage [33, 34]. Through all the studies it is quite 
evident that plasmids are the fundamental element that is helping in mediating the 
virulence and the resistance genes among the population of the S. aureus [35–37].
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5. Treatment and future aspects
Drugs that are discussed to be used for MRSA infections are Daptomycin and 
Linezolid. Daptomycin is a synthetic drug that is the class of antibiotics that destroy 
the cell membrane ability by a calcium-dependent binding phenomenon which 
leads to bactericidal activity in a concentration-dependent way. So, one of the 
widely used antibiotics and which shows good efficacy even more than methicillin 
and vancomycin. Therefore, for any MRSA bacteremia, Daptomycin is considered 
to be very effective [38–40]. There were many topical drugs used against the MRSA 
strains. These anti MRSA drugs were quite effective. Mupirocin, is one of the anti 
MRSA topical drug which is applied on the skin for curing skin infections caused 
by S. aureus [41]. The mechanism of Mupirocin is, it binds to the isoleucyl t-RNA 
synthetase which inhibits the protein synthesis of the organisms resulting in the 
destruction of the organism [42]. Fusidic acid is another topical drug used against 
staphylococcal infections and it was reported effective as well. Fusidic acid binds 
to the elongation factor G of bacteria and interferes with the translocation process 
resulting in the inhibition of the protein synthesis [28].
Similarly, Linezolid which belongs to the oxazolidinones class predominantly 
inhibits the protein synthesis in the 50S ribosome of the cell. Linezolid shows 
a good amount of efficacy against several toxin-producing strains such as toxic 
shock syndrome toxin, Panton-Valentine leukocidin, α-hemolysin [38]. But the 
resistance against Linezolid was also observed. So, the combinatorial theory was 
taken into account. Combinatorial theory helps to mix multiple compounds to 
balance the inadequate conditions of other compounds and increase efficacy of 
drugs. The combinatorial theory started with Vancomycin and it shows synergistic 
interaction with β-lactams widely. Studies cleared that the capacity of clearing the 
MRSA infection-causing strains was not high in amount when the patients were 
only subjected to Vancomycin but in combination with β-lactams the clearance 
efficiency was much higher in amount. Combination with Vancomycin shows a 
specific effect named as Sea-Saw Effect where if the susceptibility of the vanco-
mycin is decreased which results in decrease of transcription of the mec A gene 
and this increases the susceptibility of the β- lactams [43–46]. Combination with 
the Daptomycin has also been applied to check the outcome. This combination 
was to some extent very much successful as it enhanced the destruction of both 
Daptomycin-susceptible as well as Daptomycin-non-susceptible strains of MRSA. 
This combination showed high efficacy against the clearance of the bacteremia 
from the patient’s body [47, 48].
Few drugs are in development such as Dalbavancin, Oritavancin, Tigecycline. 
Tigecycline inhibits protein synthesis and it shows broad-spectrum antibiotic 
activity. These are the possible treatments upon which the work is going on to 
reduce the resistance against the invasive MRSA. The prospect of the medication 
for S. aureus infections also lies in traditional medicines. The traditional herbal 
medicines are believed to have anti-MRSA activity. The bioactive phytoconstituents 
present in the plants such as Mansonone F from Ulmus davidiana, β-asarone from 
Acorus calamus rhizome, Prenylated flavonoids from Desmodium caudatum root, 
galloylated flavonol rhamnosides from Calliandra tergemina leaves, eupomatenoid-5 
from Piper regnellii leaves are important for the MRSA treatment as they constitute 
anti-MRSA activity [49]. Some of the new relevant information regarding the 
treatment of AMR in S. aureus has come forward. Quinopristin-dalfopristin and 
Linezolid are another set of antimicrobial agents which have come up with activity 
against the resistance in S. aureus. Both these agents are protein inhibiting agents 
and Quinopristin-dalfopristin mainly exhibits bactericidal effects and Linezolid is 
bacteriostatic. Current studies against the treatment of this disease deal with the 
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various combinations of antimicrobial agents [50]. Several compounds are known 
to inhibit the synthesis of fatty acid in bacteria and with this, two antibacterial 
agents have shown greater efficiency against S. aureus. Triclosan and Isoniazid are 
the two antimicrobial agents which target the FabI in the S. aureus. Fab I is one of 
the essential enzymes utilized in fatty acid elongation and it plays a major role in S. 
aureus. High throughput screening of the FabI inhibitors has led to come up with a 
new molecule AFN-1252 also called Affinium Pharmaceuticals was identified and 
proved to be efficient against the MRSA strains [51]. Multiple combinations were 
analyzed and several limitations emerged from those. Vancomycin and Rifampicin 
were in great demand for diagnosing MRSA infections but later on, Rifampicin 
proved not to be a better option for treating the disease as this drug is the primary 
drug given against one of the concerned diseases named Tuberculosis. This combi-
nation has exhibited higher possibilities of rising the resistance against Rifampicin 
and this was the major reason for the failure of the Vancomycin-Rifampicin combi-
nation against S. aureus. Similarly, Trimethoprim/Sulfamethoxazole and Rifampicin 
was a major failure because of the poor efficacy along with multiple side effects. 
Also, it was found to be resistant to infections. Among all this, Vancomycin is the 
only drug that is still either used in combinations or as monotherapy for treating 
MRSA infections but some of the new antibiotics such as Ceftaroline, Tedizolid, 
Plazomicin are proved to be successful among other antibiotics and are under 
research and development for further studies of treating the MRSA infections [52]. 
Other explored combinations with vancomycin have shown adverse nephrotoxic-
ity. So, it is said that intensive research is required for novel approaches against the 
treatment of resistance to S. aureus. Above all the discussed conventional therapies 
for the treatment, either majority of them were proved to be ineffective or have 
shown severe side effects in the patients.
According to the future perspective, there is an immense need for an alternative 
strategy for treating the resistance against S. aureus. Treatment methods such as 
using nanoparticles are one of the efficient ways of delivering the drug directly to 
the patients. Under the nanoparticle treatment strategy, there is a unique feature of 
using ligands that are target specific for certain receptors in bacteria. AuNPs were 
surface modified by Vancomycin helps in reducing the bacterial growth and also the 
iron oxide nanoparticles are modified with the porphyrin platinum and Vancomycin 
which results in thermal degradation of the resistance strain of S. aureus. Another 
very interesting aspect is the usage of SiRNA therapy which enhances the MRSA 
inhibition. Vancomycin nanocomplexes are proved to have effective anti-MRSA 
effects which are very new to the study of alternative strategies [53].
The major limitation or failure that rises is intrinsic mechanisms of bacterial 
resistance and the target-specific antibiotics or drugs have disappointed to come 
up with any useful product. Another unique novel approach has come forth which 
combines the genomic information on the drug target and undergo chemical 
modifications along with efficacy testing [50].
6. Conclusion
Staphylococcus aureus is a major cause of bacterial infection in humans, which 
has been able to acquire resistance to a variety of antibiotics. MSRA is an emerging 
issue globally because apart from causing nosocomial infection also emerged as one 
of the key causative agents of community-acquired infections. Antibiotic resistance 
in S. aureus involves various mechanisms which are drug efflux, expression, or 
mutation of target proteins, leading to its rapid evolution which requires innovative 
approaches to develop novel treatment methodologies. A very limited amount of 
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treatments are available for MRSA and this has become the reason for increasing 
the mortality rates. Appropriate use of the antimicrobial agents as the MDR is a 
very natural phenomenon and handling this type of phenomenon needs extra care 
to minimize the growth rate of resistant MRSA isolates further in the future. The 
development of new drugs is also in progress so that the resistance can be reduced. 
Anti MRSA topical drugs are extensively in use for treating skin infections. The 
new approaches have been initiated by the use of Fusidic acid, Linozolid against 
Staphylococcal infections.
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